Humar A, Ramcharan T, Kandaswamy R, Matas A, Gruessner R W, Gruessner A C, Sutherland D E
Department of Surgery, University of Minnesota, MMC 195, 420 Delaware St. S.E., Minneapolis, MN 55455, USA.
Am J Surg. 2001 Aug;182(2):155-61. doi: 10.1016/s0002-9610(01)00676-6.
For certain uremic diabetic patients, a sequential transplant of a kidney (usually from a living donor) followed by a cadaver pancreas has become an attractive alternative to a simultaneous transplant of both organs. The purpose of this study was to compare outcomes with simultaneous pancreas-kidney (SPK) versus pancreas after kidney (PAK) transplants to determine advantages and disadvantages of the two procedures.
Between January 1, 1994, and June 30, 2000, we performed 398 cadaver pancreas transplants at our center. Of these, 193 were SPK transplants and 205 were PAK transplants. We compared these two groups with regard to several endpoints, including patient and graft survival rates, surgical complications, acute rejection rates, waiting times, length of hospital stay, and quality of life.
Overall, surgical complications were more common for SPK recipients. The total relaparotomy rate was 25.9% for SPK recipients versus 15.1% for PAK recipients (P = 0.006). Leaks, intraabdominal infections, and wound infections were all significantly more common in SPK recipients (P = 0.009, P = 0.05, and P = 0.01, respectively, versus PAK recipients). Short-term pancreas graft survival rates were similar between the two groups: at 1 year posttransplant, 78.0% for SPK recipients and 77.9% for PAK recipients (P = not significant). By 3 years, however, pancreas graft survival differed between the two groups (74.1% for SPK and 61.7% for PAK recipients), although this did not quite reach statistical significance (P = 0.15). This difference in graft survival seemed to be due to increased immunologic losses for PAK recipients: at 3 years posttransplant, the incidence of immunologic graft loss was 16.2% for PAK versus 5.2% for SPK recipients (P = 0.01). Kidney graft survival rates were, however, better for PAK recipients. At 3 years after their kidney transplant, kidney graft survival rates were 83.6% for SPK and 94.6% for PAK recipients (P = 0.001). The mean waiting time to receive the pancreas transplant was 244 days for SPK and 167 days for PAK recipients (P = 0.001).
PAK transplants are a viable option for uremic diabetics. While long-term pancreas graft results are slightly inferior to SPK transplants, the advantages of PAK transplants include the possibility of a preemptive living donor kidney transplant, better long-term kidney graft survival, significantly decreased waiting times, and decreased surgical complication rates. Use of a living donor for the kidney transplant expands the donor pool. Improvements in immunosuppressive regimens will hopefully eliminate some of the difference in long-term pancreas graft survival between SPK and PAK transplants.
对于某些尿毒症糖尿病患者,先进行肾脏移植(通常来自活体供体),随后进行尸体胰腺移植,已成为一种比同时进行两个器官移植更具吸引力的选择。本研究的目的是比较同期胰肾联合移植(SPK)与肾后胰腺移植(PAK)的结果,以确定这两种手术的优缺点。
在1994年1月1日至2000年6月30日期间,我们中心进行了398例尸体胰腺移植。其中,193例为SPK移植,205例为PAK移植。我们比较了这两组在几个终点指标方面的情况,包括患者和移植物存活率、手术并发症、急性排斥反应率、等待时间、住院时间和生活质量。
总体而言,SPK受者的手术并发症更为常见。SPK受者的再次剖腹手术总发生率为25.9%,而PAK受者为15.1%(P = 0.006)。渗漏、腹腔内感染和伤口感染在SPK受者中均明显更为常见(分别与PAK受者相比,P = 0.009、P = 0.05和P = 0.01)。两组的短期胰腺移植物存活率相似:移植后1年,SPK受者为78.0%,PAK受者为77.9%(P = 无显著性差异)。然而,到3年时,两组的胰腺移植物存活率有所不同(SPK为74.1%,PAK受者为61.7%),尽管这尚未达到统计学显著性(P = 0.15)。移植物存活率的这种差异似乎是由于PAK受者的免疫性丢失增加:移植后3年,PAK的免疫性移植物丢失发生率为16.2%,而SPK受者为5.2%(P = 0.01)。然而,PAK受者的肾脏移植物存活率更好。在肾脏移植后3年,SPK的肾脏移植物存活率为83.6%,PAK受者为94.6%(P = 0.001)。接受胰腺移植的平均等待时间,SPK为244天,PAK受者为167天(P = 0.001)。
PAK移植是尿毒症糖尿病患者的一种可行选择。虽然长期胰腺移植物结果略逊于SPK移植,但PAK移植的优点包括有可能进行优先的活体供体肾脏移植、更好的长期肾脏移植物存活率、显著缩短的等待时间以及降低的手术并发症发生率。使用活体供体进行肾脏移植扩大了供体库。免疫抑制方案的改进有望消除SPK和PAK移植在长期胰腺移植物存活率方面的一些差异。